FRIDAY, JUNE 7, 2019

6:30 p.m.-8:30 p.m.
**Identifying Nonalcoholic Steatohepatitis (NASH) in Patients with Diabetes—What You Need to Know**

*Jointly provided by The Postgraduate Institute for Medicine and Integritas Communications*

*Supported by an educational grant from Gilead Sciences, Inc.*

*(6:30 p.m.-7:00 p.m.—Registration and Dinner/7:00 p.m.-8:30 p.m.—Program)*

This discussion-based symposium will review the relationship between NASH and diabetes and provide strategies to identify patients at highest risk of NASH, including details regarding noninvasive screening methods. Expert faculty will discuss existing management strategies for these patients, providing practical recommendations for clinicians who treat patients with diabetes and NASH.

**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom 9-15

**Contact:** Mara Simpson/e-mail: msimpson@integritasgrp.com

---

6:30 p.m.-9:00 p.m.
**Metas Optimas de Tratamiento—¿Cómo Alcanzarlas en el 2019?**

*Jointly Sponsored by the University of Texas Southwestern Medical Center and Worldwide Initiative for Diabetes Education*

*Supported by an unrestricted educational grant from Novo Nordisk A/S*

*(6:30 p.m.-7:00 p.m.—Registration and Dinner/7:00 p.m.-9:00 p.m.—Educational Program)*

La creciente prevalencia de A1C sin control y el aumento en la complejidad de tratamientos disponibles para DMT2 crean un reto importante, principalmente en pacientes de países latinoamericanos. Las recomendaciones de guías actualizadas y las terapias de combinación de dosis fijas son herramientas cruciales para superar la inercia clínica, lograr un mejor control glucémico y mejorar los resultados cardiovasculares en los pacientes.

**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom 1-8

**Contact:** Jane Savio/e-mail: jane.savio@worldwidediabetes.org

Mark Vinciguerra/e-mail: Mark.Vinciguerra@UTSouthwestern.edu

---

6:30 p.m.-9:00 p.m.
**New Options and Strategies for Cardiovascular Risk Reduction in Diabetes: What the Data Tell Us**

*Sponsored by Medtelligence, Inc.*

*Supported by an educational grant from Amarin Pharma, Inc.*

*(6:30 p.m.-7:00 p.m.—Registration and Dinner/7:00 p.m.-9:00 p.m.—Program)*

This interactive, CME-certified symposium, developed for advanced-level clinicians, will focus on the complex interrelationship between cardiovascular disease and type 2 diabetes. The multidisciplinary faculty will address complex issues that challenge health care providers in caring for patients with elevated atherogenic cholesterol and triglycerides, many of whom have been sub-optimally managed. The program will describe new strategies and contemporary pharmacologic approaches with the potential to minimize cardiovascular events in patients with diabetes.

**Location:** Intercontinental San Francisco, Grand Ballroom

**Contact:** Kathleen Wickman/e-mail: kwickman@medtelligence.net
6:30 p.m.-9:30 p.m.
Cardiovascular Risk Reduction with SGLT2 Inhibitors and GLP-1 Receptor Agonists: Taking A Closer Look
Sponsored by Voxmedia
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
(6:30 p.m.-7:00 p.m.—Dinner/7:00 p.m.-9:30 p.m.—Program)

Chair, Dr. Lawrence Leiter, Dr. David Cherney, Dr. Melanie Davies, Dr. Darren McGuire, and Davida Kruger, NP, will explain the importance of recognizing ASCVD, HF, and CKD in T2D patients; interpret evidence from CVOTs; explore potential mechanisms by which SGLT2 inhibitors and GLP-1 RAs reduce cardiorenal risk; and reveal strategies for effective patient-centered, collaborative care.
**Location:** San Francisco Marriott Marquis, Golden Gate Ballroom AB
**Contact:** Tammy Thompson /e-mail: tthompson@voxmedia.us

**SATURDAY, JUNE 8, 2019**

5:30 a.m.-7:45 a.m.
Real Time Continuous Glucose Monitoring: New Clinical Outcomes, Progress Toward Automated Insulin Delivery and Trendsetting with Interoperability
Sponsored by Cognimed Inc.
Supported by an educational grant from Dexcom, Inc.
(5:30 a.m.-6:00 a.m.—Registration and Breakfast/6:00 a.m.-7:45 a.m.—Program)

COMISAIR study: outcomes of the longest clinical outcome study in CGM; Progress toward automated insulin delivery and full closed loop: a global perspective; The newest trend in diabetes technology: interoperability. Why is it important?
**Location:** Intercontinental San Francisco, Grand Ballroom
**Contact:** Jeffrey Rosenberg/e-mail: info@cgmeducation.net

6:15 p.m.-8:45 p.m.
Clinical Issues™—Multidimensional Issues in Type 2 Diabetes—Debates and Discussions Around Cardiovascular and Renal Outcomes
Sponsored by Integritas Communications
Supported by an educational grant from AstraZeneca
(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-8:45 p.m.—Program)

This Clinical Issues™ symposium will address multisystem consequences of type 2 diabetes, namely CVD, CKD, and heart failure, as well as results of SGLT2 inhibitor CV outcomes trials. Following this program, attendees should understand the role of maladaptive glucose reabsorption, the relationship between common comorbidities associated with T2DM, and application of SGLT2 inhibitors in clinical practice.
**Location:** San Francisco Marriott Marquis, Golden Gate Ballroom
**Contact:** Christa Master/e-mail: cmaster@integritasgrp.com

6:15 p.m.-8:45 p.m.
Clinical Management of Carbohydrate Restriction in Type 2 Diabetes
Sponsored by Virta Health
Supported by an educational grant from Virta Health
(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-8:45 p.m.—Program)

Recent clinical trials have demonstrated that medically-supervised individualized carbohydrate restriction can reverse type 2 diabetes (T2D) symptoms while allowing elimination of glycemic control medicines. The ADA’s 2019 Standards of Care added low carbohydrate nutrition to recommended dietary patterns for T2D. This activity will provide underlying evidence and clinical implementation details.
**Location:** San Francisco Marriott Marquis, Yerba Buena Ballroom 9-15
6:15 p.m.-8:45 p.m.
Patient-Centered Approaches to Long-Term Success in Weight Loss: “The Time Has Come,” the Walrus Said, “to Talk of Many Things”
Sponsored by Endocrine Society
Supported by an educational grant from Novo Nordisk
(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-8:45 p.m.—Program)

Through innovative clinic-based scenarios with the faculty, a patient actor, and a fellow, this program provides learners patient-centered strategies on how to manage obesity and its comorbidities, implement evidence-based pharmacotherapy strategies, and overcome challenges in long-term successful weight loss maintenance. The symposium is accredited for 2.0 AMA PRA Category 1 Credits™ and 2.0 ABIM MOC Points and is chaired by Dr. William T. Donahoo.

Location: Intercontinental San Francisco, Grand Ballroom
Contact: Cassandre Destin/e-mail: cdestin@endocrine.org

6:15 p.m.-9:00 p.m.
Translating Evidence- and Technology-Based Innovations in Continuous Glucose Monitoring
Sponsored by CMEducation Resources
Supported by an educational grant from Abbott
(6:15 p.m.-6:45 p.m.—Dinner/6:45 p.m.-9:00 p.m.—Program)

This CME dinner program will focus on emerging digital, real time, and sensor patch-based technologies for continuous monitoring of glucose levels, to improve drug interventions for diabetic patients, minimize risks of hypoglycemia, maximize time in target range for blood glucose, and to optimize treatment interventions and drug titration and selection.

Location: San Francisco Marriott Marquis, Yerba Buena Ballroom 1-8
Contact: Milo Falcon/e-mail: milo.falcon@pharmatecture.net